Noah Stansfield

3 days ago | cgtlive.com | James Beck |Noah Stansfield |Isabella Ciccone

The PD GENEration study, which is led by the Parkinson’s Foundation in collaboration with the Global Parkinson’s Genetics Program (GP2), provides whole genome sequencing (WGS) and genetic counseling for patients with Parkinson disease (PD) across more than 8 countries in the Americas and Israel. In order to support expansion internationally, the study adapted counseling materials tailored to local languages, cultural contexts, and healthcare infrastructure.

6 days ago | cgtlive.com | Noah Stansfield

According to the World Ovarian Cancer Coalition, at a global scale ovarian cancer is the 8th most common cancer for women and the 8th most common cause of death from cancer for women. Each year around the world, approximately 207,000 women with ovarian cancer die. Although treatment options exist, substantial unmet need remains, and many companies and academic institutions are currently pursuing new treatment approaches for the disease.

1 week ago | cgtlive.com | Noah Stansfield

The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive®’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more. Have a cell and gene therapy news update you’d like to share with our editorial team?

1 week ago | cgtlive.com | Noah Stansfield

Bloomsbury Genetic Therapies, a biotech company developing several gene therapy candidates for ultra-orphan rare diseases, is in the process of shutting down its operations.1The announcement came via a LinkedIn post made by the company’s cofounder and chief executive officer, Adrien Lemoine, MSc, who noted alongside the news that he will be stepping down from his role as CEO.

1 week ago | cgtlive.com | Noah Stansfield

Neurophth is currently evaluating NR082 (also known as Opvika and esonadogene mvoparvovec), an investigational gene therapy intended for the treatment of Leber hereditary optic neuropathy (LHON) associated with mtND4 mutations, in the phase 1/2/3 GOLD clinical trial (NCT04912843).1 For Healthy Vision Month, observed annually in May by the patient and clinician communities, CGTLive® has decided to take a closer look at this ongoing clinical trial.